BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 27, 2025
See today's BioWorld
Home
» Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod
To read the full story,
subscribe
or
sign in
.
Centocor’s Remicade Receives Third Rheumatoid Arthritis Nod
March 1, 2002
By
Brady Huggett
Centocor Inc.’s Remicade is inflating - both in uses and sales - having received a third approval in a rheumatoid arthritis indication. (BioWorld Today)
BioWorld